Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cardior Pharmaceuticals

Request full access

Non-coding RNA-based therapeutics in heart failure

Hanover, GermanyFounded 2016Biotech & Life Sciences

About Cardior Pharmaceuticals

Cardior is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of innovative treatments for heart disease. The company's primary market is the medical and pharmaceutical industry, with its clients being healthcare providers and institutions seeking advanced solutions for cardiovascular conditions.

Cardior's business model revolves around the research, development, and commercialization of therapeutic solutions for heart disease. The company's main revenue stream comes from the sale of its proprietary treatments to healthcare providers. Additionally, Cardior also generates income through partnerships with other pharmaceutical companies and research institutions.

One of the company's key assets is its lead candidate, CDR132L, which is currently undergoing a Phase 2 study named HF-REVERT. This study aims to evaluate the effectiveness of CDR132L in treating heart disease. The addition of Leon Carayannopoulos, a seasoned professional in the pharma industry with a strong background in translational development and clinical pharmacology, to the Board of Directors, further strengthens Cardior's position in the market.

Cardior is also active in the conference circuit, participating in major healthcare events such as the Annual J.P. Morgan Healthcare Conference. These events provide the company with opportunities to showcase its work, network with industry professionals, and attract potential investors.

Source: Dealroom company data

Cardior Pharmaceuticals in the Hanover ecosystem

Live from Dealroom

The Cardior Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • European Commission

Series A9 investors entered at this stage

  • EQT Life Sciences
  • Bristol-Myers Squibb
  • HTGF
  • Inkef
  • BioMedVC
  • FundPlus
  • Coparion
  • Hadean Ventures
  • Sunstone Life Science Ventures

Series B and later10 investors entered at this stage

  • Medizinische Hochschule Hannover
  • BioMedVC
  • Max Planck Institute for Gravitational Physics
  • Coparion
  • FundPlus
  • Max Planck Society
  • Hadean Ventures
  • Inkef
  • Max Planck Innovation
  • Sunstone Life Science Ventures
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$4M

3 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Cardior Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.